Clinical Trial Update: A Trial of JX-594 in Refractory Colorectal Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 trial of JX-594 (Pexa-Vec) in patients with refractory colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• JX-594

Snippet

Sponsor: Samsung Medical Center | Conditions: Colorectal Carcinoma | Phase 1 | Status: COMPLETED